SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 9, 2019
Emmaus Life Sciences, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
|(Commission File Number)||
|21250 Hawthorne Boulevard, Suite 800, Torrance,
|(Address of principal executive offices)||(Zip Code)|
Registrant’s telephone number, including area code (310) 214-0065
(Former name or former address, if changed, since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|☐||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|☐||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|☐||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|☐||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))|
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol||Name of each exchange on which registered|
|Common Stock, $0.001 par value||EMMA||The NASDAQ Capital Market|
|Warrants to purchase common stock||EMMAW||The NASDAQ Capital Market|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
As previously reported, on July 18, 2019, Emmaus Life Sciences, Inc. (“we,” “our,” “us,” “Emmaus” or the “company”) received a notice of noncompliance from the Listing Qualifications Staff of The Nasdaq Stock Market (the “Staff”) indicating that the company was not compliant with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) for continued listing of the company common stock on The Nasdaq Capital Market and was not in compliance with the minimum Round Lot holder requirement for continued listing of the company publicly traded warrants. The company timely filed an appeal of the Staff’s determination, which appeal was heard on September 5, 2019.
On September 9, 2019, the company was notified that the Nasdaq Hearing Panel declined to reverse the Staff’s determination to delist the company securities. As a result, the company common stock and warrants will be suspended from trading on The Nasdaq Capital Market as of the opening of trading on September 11, 2019. It is expected that the company common stock and warrants will be eligible for quotation on the OTC Market as of that date.
Item 8.01 Other Events.
On September 10, 2019, the company issued a press release announcing the Hearing Panel’s decision. A copy of the press release is filed as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
See the accompanying Index to Exhibits, which information is incorporated herein by reference.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: September 10, 2019||Emmaus Life Sciences, Inc.|
|By:||/s/ JOSEPH C. SHERWOOD III|
|Name:||Joseph C. Sherwood III|
|Title:||Chief Financial Officer|
INDEX TO EXHIBITS
|Exhibit||Incorporated by Reference||Filed/|
|Number||Exhibit Description||Form||File No.||Exhibit||Filing Date||Furnished|
|99.1||Press Release dated September 10, 2019||*|
* Filed herewith.